Opdivo-话题@MedSci

#Opdivo#

81篇内容 | 2648人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2231531, encodeId=d244223153140, content=<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a> <a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=NEJM：Opdivo与化疗联用一线治疗晚期经典型霍奇金淋巴瘤，2年总生存率达99%, objectType=article, longId=847625, objectId=7c8d84e6250a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241016/d4e0c26a886a49c5a44c789d4448efe2-g6noXwy2zM8y.jpg, objectUrl=/article/show_article.do?id=7c8d84e6250a, replyNumber=0, likeNumber=77, createdTime=2024-10-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=7c8d84e6250a, moduleTitle=NEJM：Opdivo与化疗联用一线治疗晚期经典型霍奇金淋巴瘤，2年总生存率达99%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8d84e6250a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1303113, encodeId=e682130311364, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, objectType=article, longId=302278, objectId=941a3022e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941a3022e85a, replyNumber=0, likeNumber=87, createdTime=2022-04-04, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941a3022e85a, moduleTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941a3022e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303112, encodeId=9efc1303112b4, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, objectType=article, longId=299738, objectId=b3b3299e38c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b3299e38c5, replyNumber=0, likeNumber=96, createdTime=2022-03-01, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b3299e38c5, moduleTitle=CHMP支持Opdivo治疗食管、尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b3299e38c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303111, encodeId=d7ce13031110b, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=93, createdTime=2021-12-02, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303110, encodeId=734c1303110cd, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, objectType=article, longId=218568, objectId=c15d218568ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d218568ba, replyNumber=0, likeNumber=76, createdTime=2021-10-16, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d218568ba, moduleTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15d218568ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303109, encodeId=9fe4130310906, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, objectType=article, longId=207706, objectId=989b20e706d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989b20e706d8, replyNumber=0, likeNumber=94, createdTime=2021-03-01, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989b20e706d8, moduleTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989b20e706d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303108, encodeId=cb53130310844, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, objectType=article, longId=206244, objectId=febb2062446f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=febb2062446f, replyNumber=0, likeNumber=64, createdTime=2021-01-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=febb2062446f, moduleTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=febb2062446f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303107, encodeId=193f130310ea9, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌, objectType=article, longId=206187, objectId=73a020618e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a020618e5c, replyNumber=0, likeNumber=77, createdTime=2021-01-26, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a020618e5c, moduleTitle=FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a020618e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303106, encodeId=bec5130310690, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, objectType=article, longId=205631, objectId=e7872056314a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7872056314a, replyNumber=0, likeNumber=104, createdTime=2021-01-13, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7872056314a, moduleTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7872056314a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303105, encodeId=ed731303105b4, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, objectType=article, longId=203219, objectId=4e11203219e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e11203219e6, replyNumber=0, likeNumber=97, createdTime=2020-11-11, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e11203219e6, moduleTitle=Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e11203219e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303104, encodeId=02f8130310432, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, objectType=article, longId=202354, objectId=f8f120235495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f120235495, replyNumber=0, likeNumber=76, createdTime=2020-10-23, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f120235495, moduleTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f120235495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303103, encodeId=88761303103ab, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, objectType=article, longId=201929, objectId=558820192924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558820192924, replyNumber=0, likeNumber=70, createdTime=2020-10-12, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558820192924, moduleTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=558820192924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303102, encodeId=21341303102c2, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, objectType=article, longId=201577, objectId=bce42015e75f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce42015e75f, replyNumber=0, likeNumber=71, createdTime=2020-10-05, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce42015e75f, moduleTitle=FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce42015e75f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303101, encodeId=61201303101e7, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！, objectType=article, longId=199180, objectId=0851199180c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0851199180c7, replyNumber=0, likeNumber=84, createdTime=2020-08-12, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0851199180c7, moduleTitle=Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0851199180c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303100, encodeId=ecb41303100eb, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=83, createdTime=2020-08-06, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303099, encodeId=cb8f1303099c3, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=89, createdTime=2020-06-13, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303098, encodeId=a545130309860, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=88, createdTime=2020-05-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303097, encodeId=de26130309e34, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=95, createdTime=2020-05-18, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303096, encodeId=c4df1303096f4, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=75, createdTime=2020-05-17, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303095, encodeId=12c6130309590, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, objectType=article, longId=192743, objectId=597a192e43e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597a192e43e8, replyNumber=0, likeNumber=68, createdTime=2020-04-24, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597a192e43e8, moduleTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597a192e43e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Opdivo

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#霍奇金淋巴瘤# #Opdivo#

NEJM：Opdivo与化疗联用一线治疗晚期经典型霍奇金淋巴瘤，2年总生存率达99%

2024-10-18发表于威斯康星

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）

2022-04-04

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

CHMP支持Opdivo治疗食管、尿路上皮癌

2022-03-01

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2021-12-02

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者

2021-10-16

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见

2021-03-01

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌

2021-01-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准Opdivo联合Cabometyx用于治疗晚期肾细胞癌

2021-01-26

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药

2021-01-13

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo联合Yervoy：欧洲获批一线治疗转移性非小细胞肺癌

2020-11-11

智慧医人 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审

2020-10-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益

2020-10-12

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准Opdivo联合Yervoy治疗恶性胸膜间皮瘤

2020-10-05

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo联合Yervoy显著延长胸膜间皮瘤患者存活率！

2020-08-12

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌

2020-06-13

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!

2020-05-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-18

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2020-05-17

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功

2020-04-24

科室
- - 订阅+
  - 更多科室
工具
服务